Verastem Oncology Announces Late-Breaking Oral Presentation of RAMP 201 Low-Grade Serous Ovarian Cancer Molecular Profiling and Tumor Biomarker Analysis at IGCS 2026 Annual Global Meeting
Verastem Inc VSTM
$7.74
▼ -0.77%
($-0.06)
🔥 High Short Interest
Open
$7.86
Prev Close
$7.80
Day Range
$7.67 – $7.89
52W Range
$3.43 – $10.82
Market Cap
$529.00M
Beta
0.59
EPS (TTM)
$-2.46
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2011-11-08 |
| Shares Out. | 87,870,000 |
| Website | verastem.com/ ↗ |
| Phone | 13026587581 |
| Employees | 102 |
| Revenue | $40.1M |
| Gross Profit | $36.0M |
| Net Income | -$34.7M |
| Free Cash Flow | -$162.2M |
| Total Assets | $206.5M |
| Total Liabilities | $156.5M |
| Equity | $50.0M |
About Verastem Inc
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.
Verastem Inc is a publicly traded company under the ticker symbol VSTM on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
15 analysts (2026-09-01)